37 results
8-K/A
EX-99.3
CRVO
CervoMed Inc
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
”) Total Recall and Delayed Recall. In the analysis of CSF biomarkers, there were statistically significant effects of neflamapimod treatment … -scores of HVLT total recall and delayed recall) and the major secondary endpoint of change in Wechsler Memory Scale Combined Immediate and Delayed
8-K/A
EX-99.2
CRVO
CervoMed Inc
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
trials or costly post-marketing testing and surveillance to monitor the safety and efficacy of the product;
the Company may decide to recall such product … , including the Company’s CMOs, fail to comply fully with applicable regulations, then the Company may be required to initiate a recall or withdrawal
424B3
bs5jcy
13 Jul 23
Prospectus supplement
4:32pm
S-4/A
s5tgz7o4f79
22 Jun 23
Registration of securities issued in business combination transactions (amended)
9:46pm
S-4
4wc40js9bn7 o0
10 May 23
Registration of securities issued in business combination transactions
9:56pm
PRRN14A
kmsjh6rmm6b v3t05
6 Dec 22
Revised preliminary proxy statement filed by non-management
8:30am
PRRN14A
ou4au 3fuid
2 Dec 22
Revised preliminary proxy statement filed by non-management
2:36pm
PREC14A
ftu9jl8
23 Nov 22
Preliminary proxy with contested solicitation
11:26am
8-K
EX-99.1
5e8vb
13 Sep 21
Diffusion Pharmaceuticals Issues Letter to Shareholders
4:09pm
8-K
EX-1.1
wiicgad5ub 7nuvv114f
18 Feb 21
Diffusion Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock
4:52pm
8-K
EX-10.1
p7ar4j
20 May 20
Diffusion Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
5:22pm
8-K
EX-10.1
9dz0xg539sn4gs66a
13 Dec 19
Diffusion Pharmaceuticals Inc. Announces $3.5 Million Registered Direct Offering Priced At-the-Market
4:19pm
8-K
EX-10.2
rx1uxttrxmv26
13 Nov 19
Diffusion Pharmaceuticals Announces $4.0 Million Public Offering
5:00pm